Nexus Finance
FRE.DE Fresenius SE & Co. KGaA I | DE0005785604

Company Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Latest News

Sector Healthcare
Industry Medical Care Facilities
Website https://www.fresenius.com
Audit Risk 1
Board Risk 4
Overall Risk 1
Market Cap 25.14B
Trailing P/E 16.66
Forward P/E 11.42
Dividend Rate 1.05
Dividend Yield 2.40%
Trailing Annual Div. Rate 1.05
Trailing Annual Div. Yield 2.40%
Trailing EPS 2.68
Forward EPS 3.91
Book Value 35.12
Price-to-Book 1.27
Enterprise-to-Revenue 1.53
Enterprise-to-EBITDA 11.6
Ex-Dividend Date 05/25/2026
Earnings Date 08/05/2026
Earnings Call Date 08/05/2026
Earnings Average 0.91
Earnings Low 0.87
Earnings High 0.97
Revenue Average 5.83B
Revenue Low 5.81B
Revenue High 5.85B
ende